JP2011526919A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526919A5 JP2011526919A5 JP2011516842A JP2011516842A JP2011526919A5 JP 2011526919 A5 JP2011526919 A5 JP 2011526919A5 JP 2011516842 A JP2011516842 A JP 2011516842A JP 2011516842 A JP2011516842 A JP 2011516842A JP 2011526919 A5 JP2011526919 A5 JP 2011526919A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- compound according
- acute
- compound
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002193 Pain Diseases 0.000 claims description 68
- 150000001875 compounds Chemical class 0.000 claims description 58
- 230000036407 pain Effects 0.000 claims description 55
- 230000001154 acute effect Effects 0.000 claims description 20
- 208000008035 Back Pain Diseases 0.000 claims description 12
- 230000001684 chronic effect Effects 0.000 claims description 12
- 208000004296 neuralgia Diseases 0.000 claims description 11
- 125000001475 halogen functional group Chemical group 0.000 claims description 8
- 208000005298 acute pain Diseases 0.000 claims description 7
- 206010019233 Headaches Diseases 0.000 claims description 6
- 208000004404 Intractable Pain Diseases 0.000 claims description 6
- 208000019695 Migraine disease Diseases 0.000 claims description 6
- 206010028836 Neck pain Diseases 0.000 claims description 6
- 208000004550 Postoperative Pain Diseases 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 206010027599 migraine Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 208000021722 neuropathic pain Diseases 0.000 claims description 6
- 208000009935 visceral pain Diseases 0.000 claims description 6
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 5
- 230000001272 neurogenic effect Effects 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 208000000003 Breakthrough pain Diseases 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 4
- 208000006561 Cluster Headache Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- 208000007914 Labor Pain Diseases 0.000 claims description 4
- 208000008930 Low Back Pain Diseases 0.000 claims description 4
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 4
- 208000008765 Sciatica Diseases 0.000 claims description 4
- 108010052164 Sodium Channels Proteins 0.000 claims description 4
- 102000018674 Sodium Channels Human genes 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 230000002981 neuropathic effect Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 208000004998 Abdominal Pain Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010003011 Appendicitis Diseases 0.000 claims description 2
- 208000006820 Arthralgia Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010006002 Bone pain Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 206010064012 Central pain syndrome Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 206010008479 Chest Pain Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000024720 Fabry Disease Diseases 0.000 claims description 2
- 206010016059 Facial pain Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 206010019909 Hernia Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 206010021639 Incontinence Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000035945 Labour pain Diseases 0.000 claims description 2
- 206010024229 Leprosy Diseases 0.000 claims description 2
- 206010026749 Mania Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 2
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 2
- 206010061533 Myotonia Diseases 0.000 claims description 2
- 208000005890 Neuroma Diseases 0.000 claims description 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 2
- 206010033557 Palpitations Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 208000000450 Pelvic Pain Diseases 0.000 claims description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 206010037779 Radiculopathy Diseases 0.000 claims description 2
- 206010038419 Renal colic Diseases 0.000 claims description 2
- 206010040037 Sensory neuropathy hereditary Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 206010043269 Tension headache Diseases 0.000 claims description 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 208000025609 Urogenital disease Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 210000001015 abdomen Anatomy 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000034757 axonal type 2FF Charcot-Marie-Tooth disease Diseases 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 201000000182 femoral cancer Diseases 0.000 claims description 2
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 claims description 2
- 201000006847 hereditary sensory neuropathy Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000003243 intestinal obstruction Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 208000015706 neuroendocrine disease Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 208000020629 overactive bladder Diseases 0.000 claims description 2
- 208000027753 pain disease Diseases 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000001297 phlebitis Diseases 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000005198 spinal stenosis Diseases 0.000 claims description 2
- 230000007863 steatosis Effects 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 230000002123 temporal effect Effects 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 208000026533 urinary bladder disease Diseases 0.000 claims description 2
- 206010059604 Radicular pain Diseases 0.000 claims 1
- 230000005176 gastrointestinal motility Effects 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- XXXYTJWRFBDEIQ-ZETCQYMHSA-N Clc1cc(Cl)cc([C@@H]2CNCC2)c1 Chemical compound Clc1cc(Cl)cc([C@@H]2CNCC2)c1 XXXYTJWRFBDEIQ-ZETCQYMHSA-N 0.000 description 2
- IGGITLBQEJIWMP-UHFFFAOYSA-N O=C(CCC1)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O Chemical compound O=C(CCC1)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O IGGITLBQEJIWMP-UHFFFAOYSA-N 0.000 description 2
- DIPBZRFENUVMIY-LFABVHOISA-N O=C([C@H](CC1)N(CC2)CC2c(cc2)ccc2F)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O Chemical compound O=C([C@H](CC1)N(CC2)CC2c(cc2)ccc2F)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O DIPBZRFENUVMIY-LFABVHOISA-N 0.000 description 2
- GECZPYDHACICBN-LFABVHOISA-N O=C([C@H](CC1)N(CC2)CC2c2cccc(Cl)c2)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O Chemical compound O=C([C@H](CC1)N(CC2)CC2c2cccc(Cl)c2)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O GECZPYDHACICBN-LFABVHOISA-N 0.000 description 2
- DVPLZFXUNFBMJJ-ZYZRXSCRSA-N O=C([C@H](CC1)N(CC2)CC2c2ccccc2)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O Chemical compound O=C([C@H](CC1)N(CC2)CC2c2ccccc2)N1c(cc1)ccc1S(Nc1ncc[s]1)(=O)=O DVPLZFXUNFBMJJ-ZYZRXSCRSA-N 0.000 description 2
- 0 [*+]Nc1ncc[s]1 Chemical compound [*+]Nc1ncc[s]1 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102000004605 NAV1.1 Voltage-Gated Sodium Channel Human genes 0.000 description 1
- 108010003129 NAV1.1 Voltage-Gated Sodium Channel Proteins 0.000 description 1
- 102000000706 NAV1.3 Voltage-Gated Sodium Channel Human genes 0.000 description 1
- 108010002565 NAV1.3 Voltage-Gated Sodium Channel Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7722008P | 2008-07-01 | 2008-07-01 | |
| US61/077,220 | 2008-07-01 | ||
| PCT/US2009/049346 WO2010002956A2 (en) | 2008-07-01 | 2009-07-01 | Heterocyclic derivatives as modulators of ion channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526919A JP2011526919A (ja) | 2011-10-20 |
| JP2011526919A5 true JP2011526919A5 (https=) | 2012-08-09 |
Family
ID=41464851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516842A Pending JP2011526919A (ja) | 2008-07-01 | 2009-07-01 | イオンチャネルの阻害剤としての複素環式誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7846954B2 (https=) |
| EP (1) | EP2307412A2 (https=) |
| JP (1) | JP2011526919A (https=) |
| KR (1) | KR20110025855A (https=) |
| CN (1) | CN102099356A (https=) |
| AU (1) | AU2009266979A1 (https=) |
| CA (1) | CA2729681A1 (https=) |
| IL (1) | IL210412A0 (https=) |
| MX (1) | MX2010014193A (https=) |
| RU (1) | RU2011103451A (https=) |
| WO (1) | WO2010002956A2 (https=) |
| ZA (1) | ZA201009128B (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| MX2008003337A (es) * | 2005-09-09 | 2008-09-26 | Vertex Pharma | Derivados biciclicos como modulares de canales ionicos regulados por voltaje. |
| EP1948597A1 (en) * | 2005-10-21 | 2008-07-30 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| AU2008256937A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| EP2231655B1 (en) | 2007-11-13 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivatives and related compounds as modulators of ion channels for the treatment of pain |
| CN101910166A (zh) * | 2007-11-13 | 2010-12-08 | 沃泰克斯药物股份有限公司 | 用作钠离子通道调节剂的杂环衍生物 |
| US9056201B1 (en) | 2008-01-07 | 2015-06-16 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US10022558B1 (en) | 2008-01-07 | 2018-07-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US8602959B1 (en) | 2010-05-21 | 2013-12-10 | Robert Park | Methods and devices for delivery of radiation to the posterior portion of the eye |
| DK2227257T3 (da) | 2008-01-07 | 2013-09-30 | Salutaris Medical Devices Inc | Anordninger til minimal-invasiv ekstraokular afgivelse af stråling til den posteriore del af øjet |
| US9873001B2 (en) | 2008-01-07 | 2018-01-23 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US8608632B1 (en) | 2009-07-03 | 2013-12-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye |
| WO2009133641A1 (ja) * | 2008-04-30 | 2009-11-05 | シャープ株式会社 | 照明装置、及び表示装置 |
| USD691267S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691270S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691269S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691268S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| US8956346B2 (en) | 2010-05-14 | 2015-02-17 | Rainbow Medical, Ltd. | Reflectance-facilitated ultrasound treatment and monitoring |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| JP6215230B2 (ja) * | 2012-01-16 | 2017-10-18 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | イオンチャネルのモジュレーターとしてのピラン−スピロ環式ピペリジンアミド |
| IN2014MU01296A (https=) * | 2014-04-07 | 2015-10-09 | Praj Ind Ltd | |
| EP3484464B1 (en) | 2016-03-22 | 2020-10-28 | Merck Sharp & Dohme Corp. | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels |
| USD814637S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD814638S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD815285S1 (en) | 2016-05-11 | 2018-04-10 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| PL3458449T3 (pl) | 2016-05-20 | 2025-06-23 | Xenon Pharmaceuticals Inc. | Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne |
| WO2017202376A1 (zh) * | 2016-05-26 | 2017-11-30 | 南京明德新药研发股份有限公司 | 磺酰胺衍生物 |
| USD808528S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| USD808529S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| WO2018093694A1 (en) * | 2016-11-17 | 2018-05-24 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| CN110325531B (zh) | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| US10745392B2 (en) | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| KR20210054510A (ko) | 2018-08-31 | 2021-05-13 | 제논 파마슈티칼스 인크. | 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도 |
| MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| CN112759536A (zh) * | 2019-11-05 | 2021-05-07 | 常州锐博生物科技有限公司 | 取代的苯磺酰氯的制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2324013A (en) * | 1941-07-31 | 1943-07-13 | Sharp & Dohme Inc | Amino-substituents of sulphanil-amide derivatives |
| NL130753C (https=) * | 1965-10-19 | |||
| US8202861B2 (en) * | 2003-08-08 | 2012-06-19 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| KR20070030196A (ko) * | 2004-04-13 | 2007-03-15 | 이카겐, 인코포레이티드 | 칼륨 이온 채널 조절제로서의 폴리시클릭 피리딘 |
| KR20080015102A (ko) * | 2005-05-10 | 2008-02-18 | 버텍스 파마슈티칼스 인코포레이티드 | 이온 채널 조절인자로서의 바이사이클릭 유도체 |
| ATE527251T1 (de) * | 2005-05-16 | 2011-10-15 | Vertex Pharma | Bicyclische derivate als modulatoren von ionenkanälen |
| MX2007015726A (es) * | 2005-06-09 | 2008-03-04 | Vertex Pharma | Derivados de indano como moduladores de canales ionicos. |
| MX2008003337A (es) * | 2005-09-09 | 2008-09-26 | Vertex Pharma | Derivados biciclicos como modulares de canales ionicos regulados por voltaje. |
| RU2008118350A (ru) * | 2005-10-12 | 2009-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Бифенильные производные в качестве модуляторов потенциалзависимых ионных каналов |
| EP1948597A1 (en) * | 2005-10-21 | 2008-07-30 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| NZ593074A (en) * | 2005-12-21 | 2012-04-27 | Vertex Pharma | sulfonamide-pyrrolidone derivatives as Modulators of Ion Channels |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| EP2231655B1 (en) * | 2007-11-13 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivatives and related compounds as modulators of ion channels for the treatment of pain |
| CN101910166A (zh) * | 2007-11-13 | 2010-12-08 | 沃泰克斯药物股份有限公司 | 用作钠离子通道调节剂的杂环衍生物 |
-
2009
- 2009-07-01 RU RU2011103451/04A patent/RU2011103451A/ru not_active Application Discontinuation
- 2009-07-01 MX MX2010014193A patent/MX2010014193A/es not_active Application Discontinuation
- 2009-07-01 AU AU2009266979A patent/AU2009266979A1/en not_active Abandoned
- 2009-07-01 US US12/495,880 patent/US7846954B2/en active Active
- 2009-07-01 EP EP09774406A patent/EP2307412A2/en not_active Withdrawn
- 2009-07-01 KR KR1020117002162A patent/KR20110025855A/ko not_active Withdrawn
- 2009-07-01 WO PCT/US2009/049346 patent/WO2010002956A2/en not_active Ceased
- 2009-07-01 JP JP2011516842A patent/JP2011526919A/ja active Pending
- 2009-07-01 CA CA2729681A patent/CA2729681A1/en not_active Abandoned
- 2009-07-01 CN CN200980127869XA patent/CN102099356A/zh active Pending
-
2010
- 2010-10-28 US US12/913,869 patent/US8143297B2/en active Active
- 2010-12-20 ZA ZA2010/09128A patent/ZA201009128B/en unknown
- 2010-12-30 IL IL210412A patent/IL210412A0/en unknown
-
2012
- 2012-02-22 US US13/402,519 patent/US8343763B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526919A5 (https=) | ||
| RU2011103451A (ru) | Гетероциклические производные в качестве модуляторов ионных каналов | |
| JP2014508756A5 (https=) | ||
| JP2011503112A5 (https=) | ||
| JP2010539244A5 (https=) | ||
| JP2010528035A5 (https=) | ||
| RU2010123781A (ru) | Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли | |
| JP2011503191A5 (https=) | ||
| RU2010123876A (ru) | Гетероциклические производные в качестве модуляторов ионных каналов | |
| JP2011500598A5 (https=) | ||
| RU2016104080A (ru) | Амиды конденсированного пиперидина в качестве модуляторов ионных каналов | |
| RU2009100159A (ru) | Тиенопирамидины, полезные в качестве модуляторов ионных каналов | |
| JP2014504642A5 (https=) | ||
| JP2014508169A5 (https=) | ||
| RU2007111897A (ru) | Хиназолины, полезные в качестве модуляторов ионных каналов перекрестные ссылки на родственные заявки | |
| JP2020519661A5 (https=) | ||
| JP2025526742A (ja) | ステロール系イオン化脂質及びそれを含む脂質ナノ粒子 | |
| SI2632451T1 (en) | Use of malononitrilamides in neuropathic pain | |
| JP2017504591A5 (https=) | ||
| BRPI0507786A (pt) | composto e sais farmaceuticamente aceitáveis do mesmo, formulação farmacêutica, uso de um composto, método de tratar uma doença, e, processo para a preparação de compostos | |
| JP2008511670A5 (https=) | ||
| JP6174627B2 (ja) | （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の製造方法 | |
| JP7100635B2 (ja) | 安定な水性カプサイシン注射製剤およびその医学的使用 | |
| JP2018524342A5 (https=) | ||
| MX2020002429A (es) | Compuestos para reducir la viscosidad de las formulaciones biologicas. |